Publication details

Biomarkers in immunoglobulin light chain amyloidosis

Authors

KUFOVA Z. SEVCIKOVA T. GROWKOVA K. VOJTA P. FILIPOVA J. ADAM Zdeněk POUR Luděk PENKA Miroslav RYSAVA R. NĚMEC Pavel BROŽOVÁ Lucie VYCHYTILOVÁ Petra JURCZYSZYN A. GROSICKI S. BARCHNICKA A. HAJDUCH M. SIMICEK M. HAJEK R.

Year of publication 2017
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.14735/amko20172S60
Field Oncology and hematology
Keywords amyloidosis; genome; microRNA; plasma cell; transcriptome; immunoglobulin
Description Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.

You are running an old browser version. We recommend updating your browser to its latest version.

More info